SPI has acquired the manufacturing facility under an asset purchase agreement with Micelle Biopharma, Inc. for a consideration of US$0.5mn and will invest up to US$10mn to build incremental capabilities and add additional dosage formats.
from India Infoline News Service https://ift.tt/33VowbT
No comments:
Post a Comment